Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
08:30am, Thursday, 30'th Oct 2025
Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m.
ALLO Enables Equal Access To Secure Wi-Fi for All Students With Calix SmartTown for Education
05:00pm, Friday, 17'th Oct 2025
LINCOLN, Neb. & SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #calix--Calix, Inc. (NYSE: CALX) today announced that ALLO Communications has launched Smart Schools, an innovative program built on Calix S
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript
12:22am, Saturday, 04'th Oct 2025
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Citi's SMID Call Series 2025 October 2, 2025 1:00 PM EDT Company Participants Zachary Roberts - Executive VP of Research & Development and Chief Medical Offi
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
12:31pm, Friday, 12'th Sep 2025
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
10:45am, Monday, 08'th Sep 2025
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
08:30am, Wednesday, 27'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics: Important Catalysts Guided For Early 2026
03:02pm, Thursday, 14'th Aug 2025
I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
12:15pm, Thursday, 14'th Aug 2025
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
09:13pm, Wednesday, 13'th Aug 2025
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
04:05pm, Wednesday, 13'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
08:30am, Wednesday, 06'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
10:46am, Monday, 21'st Jul 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
12:30pm, Thursday, 12'th Jun 2025
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Squarepoint Ops LLC Sells 168,152 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)
03:36am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosu
